Vertex Pharmaceuticals Inc (VRTX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$437.80
Buy
$439.00
$-8.55 (-1.91%)
Prices updated at 03 Apr 2026, 00:58 EDT
| Prices minimum 15 mins delay
Prices in USD
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Jeffrey M Leiden, PhD
CEO
Dr. Reshma Kewalramani, M.D.
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
6,400
Head office
50 Northern Avenue
Boston
United States
02210
Key personnel
Owner name | Salary |
|---|---|
Mr. Amit K. Sachdev, J.D. Executive Vice President and Chief Patient and External Affairs Officer | 0.70m |
Mr. Bruce I. Sachs Lead Independent Director | 0.19m |
Mr. Lloyd A. Carney Independent Director | 0.14m |
Mr. Charles F. Wagner, Jr Executive Vice President, Chief Operating Officer and Chief Financial Officer | 0.97m |
Dr. Jeffrey M Leiden, PhD Executive Chairman of the Board | - |
Dr. Alan M. Garber, M.D.,PhD Independent Director | 0.12m |
Mr. Suketu Upadhyay Independent Director | 0.14m |
Mr. Michel Lagarde Independent Director | 0.12m |
Dr. David Altshuler, M.D.,PhD Executive Vice President and Chief Scientific Officer | - |
Dr. Sangeeta N. Bhatia, PhD Independent Director | 0.14m |
Ms. Diana L. McKenzie Independent Director | 0.13m |
Dr. Reshma Kewalramani, M.D. Director, President and Chief Executive Officer | 1.60m |
Mr. Jonathan Biller Executive Vice President and Chief Legal Officer | - |
Dr. Jennifer Schneider, M.D. Independent Director | 0.11m |
Dr. Ourania Tatsis, PhD Executive Vice President and Chief Regulatory and Quality Officer | - |
Dr. Carmen Bozic, M.D. Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer | 0.84m |
Ms. Nancy A. Thornberry Independent Director | 0.11m |
Ms. Kristen C. Ambrose Senior Vice President and Chief Accounting Officer | - |
Dr. E Morrow Atkinson, III, PhD Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations | - |
Mr. Duncan J. McKechnie Executive Vice President and Chief Commercial Officer | - |
Mr. Mark E. Bunnage, D.Phil. Executive Vice President and Chief Scientific Officer | - |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Capital Research and Management Company | 46,637,491 |
| Capital Group | 32,684,843 |
| Capital World Investors | 25,510,182 |
| Vanguard Group Inc | 24,105,823 |
| BlackRock Inc | 22,253,047 |
Director dealings
Date | Action |
|---|---|
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 04 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
| 04 Dec 2025 | - |
| 03 Dec 2025 | - |
| 03 Dec 2025 | - |
Please note that past performance is not a reliable indicator of future returns.
